

## SUPPLEMENTARY METHODS

### SI-1: MRI analysis

#### DSC analysis steps:

1. Conversion of signal intensity to concentration of Gd-DTPA with respect to time:

$$C_m(t) = -K * \ln\left(\frac{S(t)}{S_0}\right)$$

where  $C_m(t)$  is the measured concentration of Gd-DTPA with respect to time,  $K$  is a proportionality constant that is inversely proportional to the TE and depends on the MR scanner,  $S(t)$  is the MRI signal intensity with respect to time, and so is the baseline MRI signal before the presence of Gd-DTPA and after a steady-state magnetization has been achieved [3].

2. Arterial input function: the AIF was measured automatically, using the following algorithm:

- a. The volume with maximum  $C_m(t)$  intensity was identified (10<sup>th</sup>-13<sup>th</sup> volume). Only voxels with maximum intensity in this volume were identified as AIF candidates.
- b. Only voxels with maximum intensity higher than the 96<sup>th</sup> percentile and lower than the 99.9<sup>th</sup> percentile were included.
- c. Only voxels with a shape of sharp increase and sharp decrease were included.
- d. The AIF voxel candidates were fitted to the gamma variate function using the following equation [3]. Goodness of fit was evaluated and only voxels with  $R^2 > 0.96$  were included.

$$AIF_{fit}(t) \text{ or } C_{fit}(t) = -K(x - \Delta)^\alpha * e^{-\frac{x-\Delta}{B}} * F_{step}(x - \Delta)$$

- e. The final AIF was an average of the  $C_m(t)$  signal in the voxels passing the above criteria.
  - f. Normalization of AIF: To allow a uniform time of injection in all subjects and DSC scans, the  $C_m(t)$  was shifted in case of early/late injection to allow a uniform AIF peak at the 10<sup>th</sup> volume.
3. Gamma fitting of AIF and  $C_m$ : The AIF and  $C_m(t)$  were fitted to the gamma variate function using the gamma fit equation (see above) [3].

where  $AIF_{fit}(t)$  and  $C_{fit}(t)$  are the fitted AIF(t) and  $C_m(t)$  curves, respectively,  $K$  is a constant,  $x$  is the image number,  $\Delta$  is the delay between image 0 and the arrival of the bolus (a positive number),  $\alpha$  and  $B$  are gamma variate parameters, and  $F_{step}$  is a step function defined by:

$$F_{step} = \begin{cases} 1 & \text{for } (x - \Delta) \geq 0 \\ 0 & \text{for } (x - \Delta) < 0 \end{cases}$$

4. SVD deconvolution: The fitted AIF was used to calculate  $C(t)$  (the tissue response to an instantaneous arterial bolus) using SVD deconvolutions was done by Ostergaard et al. (1996). In short, the values for the AIF and  $C_m(t)$  curves can be written in vector notation as  $C = AIF^{-1} \cdot C_m$ , where  $C$  represents the matrix of the deconvolved  $C(t)$  curve. This equation can be solved using the SVD technique, whereby the matrix AIF is decomposed into three matrices  $AIF = U \cdot W \cdot VT$ . The inverse of AIF can be calculated as  $AIF^{-1} = V \cdot [\text{diag}(1/w_j)] \cdot UT$ , where  $[\text{diag}(1/w_j)]$  represents the reciprocals of the diagonal elements of  $W$ . When calculating  $AIF^{-1}$ , problems arise when  $W$  contains singular values (i.e.,  $w_j = 0$  or is close to 0) and will cause the curve  $C(t)$  to oscillate. Therefore, we used a cutoff threshold of 10% [1].
5. Calculation of CBV was performed based on the fitted  $C_m(t)$  and AIF:

$$CBV = \frac{\kappa}{\rho} * \frac{\int C_m(t) dt}{\int AIF(t) dt}$$

where  $\kappa = (1 - HCTLV)/(1 - HCTSV)$  corrects for the fact that the hematocrit in large vessels (HCTLV was set to 0.45) is larger than the hematocrit of small vessels (HCTSV was set to 0.25) (1) and  $\rho$  is the density of brain tissue (1.04 g/ml) [3].

6. Calculation of CBF was performed using the following equation:

$$\frac{CBV}{CBF} = \frac{\int C(t) dt}{C_{max}}$$

where  $C(t)$  is the concentration of Gd-DTPA in a tissue region and  $C_{max}$  is the maximum of this curve [3].

7. MTT was calculated [2]:

$$MTT = \frac{CBV}{CBF}$$

8. Normalization of the CBF: Since the amount of injection was not uniform between scans, the CBF was normalized using a factor of 1.9 divided by the AIF peak value.

### Supplementary References

1. Ostergaard L, Sorensen AG, Kwong KK, Weisskoff RM, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: Experimental comparison and preliminary results. *Magn Reson Med.* 1996; 36:726–36.  
<https://doi.org/10.1002/mrm.1910360511>  
PMID:[8916023](https://pubmed.ncbi.nlm.nih.gov/8916023/)

2. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. *Magn Reson Med.* 1996; 36:715–25.

<https://doi.org/10.1002/mrm.1910360510>  
PMID:[8916022](https://pubmed.ncbi.nlm.nih.gov/8916022/)

3. Smith AM, Grandin CB, Duprez T, Mataigne F, Cosnard G. Whole brain quantitative CBF, CBV, and MTT measurements using MRI bolus tracking: implementation and application to data acquired from hyperacute stroke patients. *J Magn Reson Imaging.* 2000; 12:400–10.

[https://doi.org/10.1002/1522-2586\(200009\)12:3<400::aid-jmri5>3.0.co;2-c](https://doi.org/10.1002/1522-2586(200009)12:3<400::aid-jmri5>3.0.co;2-c)  
PMID:[10992307](https://pubmed.ncbi.nlm.nih.gov/10992307/)